Responses
Regular Abstracts – Part 2
Clinical Trial In Progress
782-E Preliminary results of an in progress, first-in-human phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
